Skinhealth Systems Inc. · NASDAQ:SKIN
Skinhealth Systems — Q4 2024 Earnings Presentation
19 slides from Skinhealth Systems's earnings presentation, Mar 12, 2025
Slide 1: Fourth Quarter & Full Year 2024 Earnings Presentation
Fourth Quarter & Full Year 202 Earnings Presentation March 12, 2025
Slide 2: Disclaimer
Disclaimer This Presentation contains certain forward-looking statements. These statements may relate to, but are not limited to, expectations of future operating results or financial performance of The Beauty Health Company (the "Company’), capital expenditures, the introduction of new products, ex
Slide 3: Hydrafacial is a Medtech Meets Beauty company
Hydrafacial is a Medtech Meets Beauty company at the nexus of Beauty, Aesthetics, Wellness and Health Aesthetics Beauty Health Wellness
Slide 4: Q4 & FY 2024 Performance Update
ae BEAUTYHEALTH’ * y O4 & FY 2024 a Performance ul Update
Slide 5: Fourth Quarter 2024 Highlights
Fourth Quarter 2024 Highlights $26.8m -14% YoY -40% YoY +9% YoY +$5.6m YoY Lower delivery systems Decrease in delivery Continued year-over-year Net loss was relatively Adjusted EBITDA more net sales, partially systems net sales, as growth in consumables flat year-over-year than doubled year-over- of
Slide 6: Full Year 2024 Highlights
Full Year 2024 Highlights -16% YoY Lower delivery systems net sales, partially offset by growth in consumables 6 $125.4m -39% YoY Decrease in delivery systems net sales, as macroeconomic challenges persist, combined with the international launch of Syndeo in 2023 +9% YoY Continued year-over-year gro
Slide 7: 2024 Achievements
2024 Achievements OPERATIONAL EXCELLENCE SALES EXECUTION FINANCIAL DISCIPLINE Appointed new Chief Supply Chain & Operations Officer to improve operations Re-aligned manufacturing capacity to improve gross margins; concluded China third-party manufacturing by consolidating global manufacturing operat
Slide 8: 2025 Financial Guidance
2025 Financial Guidance $270 - $300m 1Q 2025E net sales FY 2025E net sales $10 - $25m 1Q 2025E adjusted EBITDA’ FY 2025E adjusted EBITDA' BEAUTYHEALTH 1, Adjusted EBITDA is a non-GAAP measure; please refer to the disclaimer for a discussion of the definition of this measure and important information
Slide 9: Compelling Business Model
Compelling Business Model Harnessing the power of our large device footprint and clinically effective consumables Hydrafacial aS eS By! IF 3 AK+ Hydrafacial . Hydralock HA device footprint 9 > BEAUTYHEALTH
Slide 10: Strongly Positioned in Growing Industry
Strongly Positioned in Growing Industry Our Opportunity Our Leadership global medical aesthetic market projected growth through 2029! Market Share of aesthetic practices with microdermabrasion offer Hydrafacial treatments currently2 Best-Known Bra nd of consumers agree their focus has shifted from a
Slide 11: Positioned for Long-Term Success
Positioned for Long-Term Success Nl DIFFERENTIATED LOYAL ie PRODUCT & LEADER IN LARGE, ESTHETICIANS TECHNOLOGY mio ales) = MARKET | Adored by estheticians a a Created hydradermabrasion , Vy d for attractive economics, | category with clinical Omnichannel distribution and ag / rapid equipment efficac
Slide 12: Anchored by our flagship brand, Hydrafacial
Anchored by our Asked for by name and flagship brand, Hydrafacial recommended to friends 39% 96% Brand RealSelf awareness! “Worth It” Rating? 55% 52 more Consumer conversion Net than Promoter Botox' Score? 12 BEAUTYHEALTH ‘Ipsos Study. July 2024, Base: Consumers of the aesthetic and professional bea
Slide 13: Hydrafacial continues to drive revenue for estheticians
Hydrafacial continues to d rive ‘ An esthetician performing revenue for 7, just 10 Hydrafacial treatments per week can earn $1 O O, O O O purchases more than one annually? aesthetic treatme' 64% Hydrafacial’s market share in the of clients reported a confidence Nearly half of Hydrafacia’ has the pot
Slide 14: Clinically Proven Immediate and Long-Term Results
Clinically Proven Immediate and Long-Term Results In clinical studies with participants ranging in skin types and concerns After just 1 treatment! Pore size + 100% of participants reported decreased pore size Fine lines +» 90% of participants reported decreased visible fine lines and wrinkles + 80%
Slide 15: Skin Health Benefits Beyond the Face: Hydrafacial Keravive
Skin Health Benefits Beyond the Face: Hydrafacial Keravive treatments First-of-its-kind scalp facial powered by Hydrafacial’s patented Vortex Technology The three-step, in-office treatment and at-home regimen is designed to deeply cleanse, exfoliate, and nourish the scalp THE SKINIFICATION OF THE SC
Slide 16: Appendix: Non-GAAP Financial Reconciliation
BEAUTYHEALTH ayy Appendix: Non-GAAP Financial Reconciliati Hydrafacial ie (ome,
Slide 17: Reconciliation of net loss to adjusted EBITDA
Reconciliation of net loss to adjusted EBITDA Three Months Ended December 31, Year Ended December 31, Unaudited (¢ in millions)* 2024 2023 2024 2023 Net sales $ 83.5 $ 96.8 $ 3343 $ 398.0 Net loss $ (10.3) $ (9.4) $ (29.1) $ (100.1) Adjusted to exclude the following: (Benefit) expense for income tax
Slide 18: Reconciliation of gross profit to adjusted gross profit
Reconciliation of gross profit to adjusted gross profit Three Months Ended December 31, Year Ended December 31, Unaudited (¢ in millions)! 2024 2023 2024 2023 Net sales $ 835 $968 $ 3343 «$~——(398.0 Gross profit $ 523 $ 457 $ 1823 «$155.4 Gross margin 62.7 % 47.2% 54.5% 39.0% Adjusted to exclude the
Slide 19: BEAUTYHEALTH
+ BEAUTYHEALTH